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At Risk for Huntington's Disease
HD is a genetically caused brain disorder that causes uncontrollable bodily movements and robs
people's ability to walk, talk, eat, and think. The final result is a slow, ugly death. Children of parents
with HD have a 50-50 chance of inheriting the disease. There is no cure or treatment.
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What if scientists could simply switch off a mutated gene causing a
debilitating neurodegenerative disorder like Huntington’s disease?
Known as gene (or genome) editing, that approach is a current hot
research topic, generating hope for sufferers of genetic diseases like HD.
Gene editing will be the focus of a symposium on September 4 sponsored
by life science start-up incubator Johnson & Johnson Innovation,
JLABS (hereafter simplified as JLABS) and the Janssen Pharmaceutical
Companies, the drug-discovery arm of Johnson & Johnson, in San Diego,
CA.
At the sponsors’ invitation, I will give a presentation, based on my two
decades as an HD advocate, on the health and social challenges faced by
HD-affected individuals and their families. The two firms have also invited
seven leading scientists and biotech executives to speak at the symposium,
titled “Science Alliance: Silencing Neurodegenerative Diseases and
Sensory Disorders with Gene Editing.”
HD community members can watch the live webcast of the event for free
by registering at the event website and entering the discount code
“HDCOMMUNITY” at check out. Attendance in person is $35 for the
general public and $20 for students and academics, at the JLABS facility at
3210 Merryfield Row, San Diego.
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Recent milestones in gene therapy “have ignited interest” in the field and
“especially its application to neurological disorders,” the website states.
Gene editing has opened the door to innovation in the treatment of
diseases like HD, spinal muscular atrophy, and ALS, according to the
organizers.
The website points out that, as the technology progresses, key questions
are emerging, such as how to effectively deliver gene editing drugs to the
brain.
Owned by Johnson & Johnson, JLABS provides labs, offices, marketing,
education, and events for early-stage life-science companies unaffiliated
with Johnson & Johnson. In San Diego, one of the world’s leading biotech
hubs, it offers services to 60 companies; globally, JLABS serves 580
companies.
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Gene editing is different from gene silencing, the technique used in the
Phase 3 Roche clinical trial currently in progress in the U.S. and a
projected 17 other countries (click here to read more). Roche’s RG6042 is
an antisense oligonucleotide, an artificial strand of DNA designed block
the production of the huntingtin protein in brain cells.
With gene editing, scientists make changes in the actual DNA – a
revolution in biomedical research.
The gene-editing technology currently getting the most attention – one
already used in the search for HD treatments – is known as CRISPR.
Scientists first observed CRISPR occurring naturally in bacteria in the
1990s. In 2002, scientists discovered additional DNA instructions called
“Cas.” The combination CRISPR/Cas actually comprises the bacterial
immune system. (Click here to read more.)
“There’s no equivalent of word processing software to edit genes,” then
Ph.D. candidate Leora Fox (now a Ph.D.) wrote in HDBuzz in 2017. “To fix
genes on a microscopic scale, one cell at a time, the faulty code has to be
located and physically cut – and that’s what CRISPR/Cas does.”
To alter a gene, scientists need to insert CRISPR/Cas into the cells.

(Image credit: Ernesto del Aguila III, National Human Genome Research
Institute, and Wikimedia Commons)
In a disease like HD, the goal is to use this mechanism to cut directly (that
is, shorten) the defective, elongated gene. Researchers are also looking at
other ways to deploy gene editing.
In recent years, HD research groups have used this technology to edit the
HD gene in the brains of genetically modified “HD mice”. One group
developed a technique that led to beneficial effects in mice, including the
recovery of older mice that had already developed symptoms. (Click here
to read more.)
Chinese researchers have used gene editing in human embryos to fix the
mutation behind the blood disease beta-thalassemia, which reduces the
amount of red blood cells. However, the embryos were not implanted.
Gene editing is still far from use in human clinical trials. Among the
challenges, scientists need to find ways to effectively deliver such a
treatment to the brain and avoid inadvertent editing of other genes. (Click
here to read more.)
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(Late last year a researcher in China claimed to have used CRISPR to alter
the genomes of twin baby girls through in vitro fertilization to enable them
to resist potential infection from HIV. The news of this development
sparked renewed controversy over the use of biotechnology to intervene in
human life.)
The symposium participants
To explore gene editing in neurodegenerative and sensory disorders
(difficulties with the five senses), JLABS and Janssen have invited seven
researchers and executives to the September 4 symposium, including at
least two with experience with CRISPR. They include:
Leah Aluisio, Associate Director, Janssen Research and Development;
Alexis C. Komor, Ph.D., Assistant Professor, Department of Chemistry and
Biochemistry, UCSD;
Young Jik Kwon, Ph.D., Professor, Department of Pharmaceutical
Sciences, University of California, Irvine, and co-founder, Responsive
Polymers Therapeutics, Inc., and Jupiter Therapeutics, Inc.;
Sanjay Mistry, Ph.D., Head of JLABS @ San Diego, Johnson & Johnson
Innovation, JLABS;
Gerry Rodrigues, Associate Vice President, Allergan;
Arthur Suckow, Ph.D., CEO, DTx Pharma; and
Gene Yeo, Ph.D., MBA, Professor, University of California, San Diego, and
co-founder, Locana and Eclipse Bioinnovations.
Their bios are available on the event website.
Imagining a cure?
As a speaker, I hope to portray HD’s devastating impact and the urgent
need for effective treatment.
In the HD world, scientists avoid the word “cure.” HD is so complex that
many have said a cocktail of drugs will be needed to target the multiple
problems in the brain and elsewhere in the body.
For the first time, actually switching off or completely removing a
mutation might enable us to imagine the way to a cure.

curehd.blogspot.com/2019/08/what-if-we-could-turn-off-cause-of.html

3/4

11/18/21, 2:04 PM

At Risk for Huntington's Disease: What if we could turn off the cause of Huntington’s disease?

Gene Veritas (aka Kenneth P. Serbin) (photo by Yi Sun, Ph.D.)
Posted by Gene Veritas at 9:38 PM
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